image
Healthcare - Medical - Distribution - NYSE - US
$ 82.36
-0.519 %
$ 4.07 B
Market Cap
19.99
P/E
1. INTRINSIC VALUE

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products.[ Read More ]

The intrinsic value of one PBH stock under the base case scenario is HIDDEN Compared to the current market price of 82.4 USD, Prestige Consumer Healthcare Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PBH

image
FINANCIALS
1.13 B REVENUE
-0.21%
342 M OPERATING INCOME
-0.88%
209 M NET INCOME
354.34%
249 M OPERATING CASH FLOW
8.36%
-20.1 M INVESTING CASH FLOW
-73.61%
-241 M FINANCING CASH FLOW
-29.69%
284 M REVENUE
6.14%
84.3 M OPERATING INCOME
17.06%
54.4 M NET INCOME
10.82%
69.8 M OPERATING CASH FLOW
27.43%
-2.03 M INVESTING CASH FLOW
4.84%
-51.2 M FINANCING CASH FLOW
21.86%
Balance Sheet Decomposition Prestige Consumer Healthcare Inc.
image
Current Assets 375 M
Cash & Short-Term Investments 46.5 M
Receivables 177 M
Other Current Assets 152 M
Non-Current Assets 2.94 B
Long-Term Investments 0
PP&E 89.3 M
Other Non-Current Assets 2.85 B
Current Liabilities 117 M
Accounts Payable 39 M
Short-Term Debt 12.3 M
Other Current Liabilities 65.8 M
Non-Current Liabilities 1.55 B
Long-Term Debt 1.13 B
Other Non-Current Liabilities 413 M
EFFICIENCY
Earnings Waterfall Prestige Consumer Healthcare Inc.
image
Revenue 1.13 B
Cost Of Revenue 501 M
Gross Profit 624 M
Operating Expenses 282 M
Operating Income 342 M
Other Expenses 133 M
Net Income 209 M
RATIOS
55.49% GROSS MARGIN
55.49%
30.43% OPERATING MARGIN
30.43%
18.60% NET MARGIN
18.60%
12.65% ROE
12.65%
6.31% ROA
6.31%
9.32% ROIC
9.32%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Prestige Consumer Healthcare Inc.
image
Net Income 209 M
Depreciation & Amortization 30.7 M
Capital Expenditures -9.55 M
Stock-Based Compensation 14 M
Change in Working Capital -39.8 M
Others -21.3 M
Free Cash Flow 239 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Prestige Consumer Healthcare Inc.
image
Wall Street analysts predict an average 1-year price target for PBH of $85.8 , with forecasts ranging from a low of $71 to a high of $93 .
PBH Lowest Price Target Wall Street Target
71 USD -13.79%
PBH Average Price Target Wall Street Target
85.8 USD 4.18%
PBH Highest Price Target Wall Street Target
93 USD 12.92%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.475 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Prestige Consumer Healthcare Inc.
image
Sold
0-3 MONTHS
4.31 M USD 4
3-6 MONTHS
0 USD 0
6-9 MONTHS
5.63 M USD 4
9-12 MONTHS
368 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
5 days ago
Nov 12, 2024
Sell 736 K USD
P'Pool William
See Remarks
- 8987
81.85 USD
5 days ago
Nov 12, 2024
Sell 2.02 M USD
Sacco Christine
Chief Financial Officer
- 24686
82.01 USD
5 days ago
Nov 12, 2024
Sell 743 K USD
Mekhail Adel
EVP, Marketing & Sales
- 9063
82 USD
5 days ago
Nov 12, 2024
Sell 531 K USD
Fritz Mary Beth
SVP Quality & Regulatory
- 6471
81.99 USD
5 days ago
Nov 12, 2024
Sell 280 K USD
Fritz Mary Beth
SVP Quality & Regulatory
- 3414
81.93 USD
8 months ago
Mar 01, 2024
Sell 4.37 K USD
Fritz Mary Beth
SVP Quality & Regulatory
- 62
70.43 USD
8 months ago
Mar 01, 2024
Sell 7.75 K USD
Fritz Mary Beth
SVP Quality & Regulatory
- 110
70.41 USD
8 months ago
Feb 28, 2024
Sell 17.3 K USD
Fritz Mary Beth
SVP Quality & Regulatory
- 246
70.19 USD
8 months ago
Feb 27, 2024
Sell 70 USD
Fritz Mary Beth
SVP Quality & Regulatory
- 1
70 USD
8 months ago
Feb 28, 2024
Sell 29.3 K USD
Fritz Mary Beth
SVP Quality & Regulatory
- 416
70.36 USD
8 months ago
Feb 23, 2024
Sell 770 USD
Fritz Mary Beth
SVP Quality & Regulatory
- 11
70 USD
8 months ago
Feb 26, 2024
Sell 361 K USD
Fritz Mary Beth
SVP Quality & Regulatory
- 5132
70.43 USD
8 months ago
Feb 26, 2024
Sell 320 K USD
Fritz Mary Beth
SVP Quality & Regulatory
- 4545
70.44 USD
9 months ago
Feb 15, 2024
Sell 277 K USD
Mekhail Adel
EVP, Marketing & Sales
- 4000
69.21 USD
9 months ago
Feb 15, 2024
Sell 798 K USD
Mekhail Adel
EVP, Marketing & Sales
- 11549
69.08 USD
9 months ago
Feb 14, 2024
Sell 356 K USD
Sacco Christine
Chief Financial Officer
- 5231
68.08 USD
9 months ago
Feb 14, 2024
Sell 1.7 M USD
Sacco Christine
Chief Financial Officer
- 24788
68.41 USD
9 months ago
Feb 14, 2024
Sell 839 K USD
P'Pool William
See remarks
- 12336
68.02 USD
9 months ago
Feb 14, 2024
Sell 928 K USD
P'Pool William
See remarks
- 13683
67.79 USD
9 months ago
Feb 08, 2024
Sell 368 K USD
Fritz Mary Beth
SVP Quality & Regulatory
- 5336
69 USD
1 year ago
Sep 14, 2023
Sell 150 K USD
Fritz Mary Beth
SVP Quality & Regulatory
- 2540
58.92 USD
1 year ago
Aug 08, 2023
Sell 1.45 M USD
Lombardi Ronald M.
Chief Executive Officer
- 22249
64.97 USD
1 year ago
Aug 08, 2023
Sell 238 K USD
Lombardi Ronald M.
Chief Executive Officer
- 3608
65.99 USD
1 year ago
Aug 08, 2023
Sell 338 K USD
Lombardi Ronald M.
Chief Executive Officer
- 5052
66.99 USD
1 year ago
Aug 08, 2023
Sell 128 K USD
Lombardi Ronald M.
Chief Executive Officer
- 1891
67.95 USD
1 year ago
May 24, 2023
Sell 1.55 M USD
Sacco Christine
Chief Financial Officer
- 25746
60.07 USD
1 year ago
May 24, 2023
Sell 1.1 M USD
Sacco Christine
Chief Financial Officer
- 18265
60.07 USD
1 year ago
May 19, 2023
Sell 600 K USD
Mekhail Adel
EVP, Marketing & Sales
- 10000
60 USD
1 year ago
May 19, 2023
Sell 436 K USD
Mekhail Adel
EVP, Marketing & Sales
- 7194
60.65 USD
1 year ago
May 19, 2023
Sell 600 K USD
Mekhail Adel
EVP, Marketing & Sales
- 10000
60 USD
1 year ago
May 19, 2023
Sell 472 K USD
Mekhail Adel
EVP, Marketing & Sales
- 7194
65.65 USD
1 year ago
May 15, 2023
Sell 479 K USD
Fritz Mary Beth
SVP Quality & Regulatory
- 8154
58.8 USD
1 year ago
Dec 06, 2022
Sell 898 K USD
P'Pool William
SVP, GC & Corp Secretary
- 14780
60.76 USD
1 year ago
Dec 02, 2022
Sell 882 K USD
P'Pool William
SVP, GC & Corp Secretary
- 13862
63.6 USD
1 year ago
Dec 01, 2022
Sell 388 K USD
Fritz Mary Beth
SVP Quality & Regulatory
- 6300
61.57 USD
1 year ago
Dec 01, 2022
Sell 50.1 K USD
Fritz Mary Beth
SVP Quality & Regulatory
- 814
61.57 USD
2 years ago
Nov 18, 2022
Sell 2.29 M USD
Lombardi Ronald M.
Chief Executive Officer
- 38793
59.0975 USD
3 years ago
Nov 12, 2021
Sell 3.29 M USD
Lombardi Ronald M.
Chief Executive Office
- 52367
62.78 USD
3 years ago
Mar 04, 2021
Sell 277 K USD
Fritz Mary Beth
Senior VP Quality & Regulatory
- 6505
42.58 USD
3 years ago
Mar 04, 2021
Sell 277 K USD
Fritz Mary Beth
Senior VP Quality & Regulatory
- 6505
42.58 USD
3 years ago
Mar 05, 2021
Sell 246 K USD
Fritz Mary Beth
Senior VP Quality & Regulatory
- 5759
42.8 USD
3 years ago
Dec 17, 2020
Sell 91.4 K USD
Fritz Mary Beth
Senior VP Quality & Regulatory
- 2532
36.1 USD
4 years ago
May 12, 2020
Sell 1.18 M USD
Lombardi Ronald M.
Chief Executive Officer
- 29593
40 USD
6 years ago
Nov 19, 2018
Sell 1.3 M USD
Connors Timothy
EVP, Sales & Marketing
- 34000
38.25 USD
6 years ago
Nov 13, 2018
Sell 837 K USD
Connors Timothy
EVP, Sales & Marketing
- 21307
39.26 USD
6 years ago
Nov 13, 2018
Sell 558 K USD
Connors Timothy
EVP, Sales & Marketing
- 14300
39 USD
6 years ago
Nov 14, 2018
Sell 1.52 M USD
Connors Timothy
EVP, Sales & Marketing
- 39100
38.79 USD
6 years ago
May 15, 2018
Sell 758 K USD
BOYKO JEAN A
SVP, Science and Technology
- 20528
36.91 USD
6 years ago
Feb 12, 2018
Bought 50.8 K USD
P'Pool William
SVP, Gen Counsel & Corp Sec.
+ 1500
33.9 USD
6 years ago
Feb 07, 2018
Bought 111 K USD
RICCIARDI NATALE S
Director
+ 3000
37.04 USD
6 years ago
Feb 05, 2018
Bought 149 K USD
JENNESS JAMES M
Director
+ 4200
35.47 USD
6 years ago
Feb 05, 2018
Bought 252 K USD
Lombardi Ronald M.
Chief Executive Officer
+ 7000
35.94 USD
6 years ago
Feb 05, 2018
Bought 266 K USD
COSTLEY GARY E
Director
+ 7500
35.47 USD
7 years ago
Aug 09, 2017
Sell 671 K USD
BOYKO JEAN A
SVP, Science and Technology
- 12876
52.12 USD
8 years ago
Jun 08, 2016
Sell 1.35 M USD
Parkinson John
Senior VP- International
- 25143
53.57 USD
8 years ago
Jun 08, 2016
Sell 66.6 K USD
BYOM JOHN E
Director
- 1249
53.35 USD
8 years ago
May 27, 2016
Sell 264 K USD
Cowley Samuel C
General Counsel and VP
- 4821
54.67 USD
8 years ago
May 27, 2016
Sell 269 K USD
MIGAKI PAUL
See Remarks
- 4930
54.51 USD
8 years ago
May 31, 2016
Sell 188 K USD
BOYKO JEAN A
SVP, Science and Technology
- 3500
53.78 USD
9 years ago
Jun 15, 2015
Sell 751 K USD
Parkinson John
Senior VP- International
- 16695
44.99 USD
9 years ago
Jun 10, 2015
Sell 403 K USD
Parkinson John
Senior VP- International
- 9104
44.29 USD
9 years ago
Jun 01, 2015
Sell 154 K USD
Mannelly Matthew
President and CEO
- 3502
44 USD
9 years ago
May 29, 2015
Sell 715 K USD
Mannelly Matthew
President and CEO
- 16168
44.2 USD
9 years ago
May 21, 2015
Sell 543 K USD
BOYKO JEAN A
SVP, Science and Technology
- 12583
43.12 USD
9 years ago
May 19, 2015
Sell 4.09 M USD
Mannelly Matthew
President and CEO
- 94429
43.31 USD
9 years ago
May 20, 2015
Sell 574 K USD
Mannelly Matthew
President and CEO
- 13252
43.28 USD
9 years ago
May 20, 2015
Sell 218 K USD
Mannelly Matthew
President and CEO
- 5050
43.13 USD
9 years ago
May 19, 2015
Sell 543 K USD
Cowley Samuel C
General Counsel and VP
- 12495
43.42 USD
9 years ago
May 19, 2015
Sell 3.17 M USD
Connors Timothy
EVP, Sales & Marketing
- 73648
43.11 USD
9 years ago
Feb 10, 2015
Sell 677 K USD
Mannelly Matthew
President and CEO
- 17500
38.69 USD
7. News
PBH vs. SYK: Which Stock Is the Better Value Option? Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks is more attractive to value investors? zacks.com - 5 days ago
Prestige Consumer Healthcare Inc (PBH) Q2 2025 Earnings Call Transcript Prestige Consumer Healthcare Inc (NYSE:PBH ) Q2 2025 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Phil Terpolilli - Vice President, Investor Relations Ron Lombardi - Chairman, President & Chief Executive Officer Chris Sacco - Chief Financial Officer Conference Call Participants Rupesh Parikh - Oppenheimer Susan Anderson - Canaccord Anthony Lebiedzinski - Sidoti & Co. Operator Good day, ladies and gentlemen, and welcome to Prestige Consumer Healthcare's Second Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. seekingalpha.com - 1 week ago
PBH Q2 Earnings Match Estimates, Revenues Beat, Shares Rise Prestige Consumer Healthcare's second-quarter sales are impacted by the ongoing supply chain challenges in the Clear Eyes business. zacks.com - 1 week ago
Prestige Consumer Healthcare (PBH) Meets Q2 Earnings Estimates Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.07 per share a year ago. zacks.com - 1 week ago
PBH or SYK: Which Is the Better Value Stock Right Now? Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com - 3 weeks ago
PBH vs. SYK: Which Stock Is the Better Value Option? Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now? zacks.com - 1 month ago
PBH or SYK: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now? zacks.com - 1 month ago
What Makes Prestige Consumer Healthcare (PBH) a Good Fit for 'Trend Investing' Prestige Consumer Healthcare (PBH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. zacks.com - 1 month ago
PBH or SYK: Which Is the Better Value Stock Right Now? Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now? zacks.com - 2 months ago
Here's Why 'Trend' Investors Would Love Betting on Prestige Consumer Healthcare (PBH) Prestige Consumer Healthcare (PBH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. zacks.com - 2 months ago
Prestige Consumer Healthcare Inc. (PBH) Q2 2024 Earnings Call Transcript Prestige Consumer Healthcare Inc. (NYSE:PBH ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Phil Terpolilli - Director of IR Ron Lombardi - Chairman, President & CEO Chris Sacco - CFO Conference Call Participants Rupesh Parikh - Oppenheimer Susan Anderson - Canaccord Linda Bolton-Weiser - D.A. Davidson Anthony Lebiedzinski - Sidoti & Co. Mitchell Pinheiro - Sturdivant Trevor Sahr - William Blair Operator Welcome to the Q1 2025 Prestige Consumer Healthcare Inc. Earnings Conference Call. seekingalpha.com - 3 months ago
Prestige Consumer Healthcare (PBH) Reports Q1 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 3 months ago
8. Profile Summary

Prestige Consumer Healthcare Inc. PBH

image
COUNTRY US
INDUSTRY Medical - Distribution
MARKET CAP $ 4.07 B
Dividend Yield 0.00%
Description Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Contact 660 White Plains Road, Tarrytown, NY, 10591 https://www.prestigebrands.com
IPO Date Feb. 10, 2005
Employees 570
Officers Dean Siegal Director of Communications Mr. Adel Mekhail Executive Vice President of Marketing & Sales Mr. Jeffrey Zerillo Senior Vice President of Operations Ms. Mary Beth Fritz Senior Vice President of Quality & Regulatory Affairs